Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Related Posts

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Effectiveness of mailed versus in-person PAP initiation in VA’s TeleSleep program

Gomez A, Sarmiento KF, Smith C, Mitchell M, Lee D, Totten A, Sanders E, Ryden AM, Seo J, Bhattacharyya S, Harris B, Mempin R, Moghtaderi[...]

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]